Add to ORKGfor several months despite clinically effective C5 blocking therapy. A more integrated approach addressing upstream and downstream pathways in addition to those attributable to complement activation are critical for the Magro et al. Orphanet Journal of Rare Diseases 2013, 8:18
Abstract Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim progn...
The C5 targeting monoclonal antibody eculizumab has changed the natural history of paroxysmal noctur...
Background: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis ...
Eculizumab inhibits the terminal, lytic pathway of complement by blocking the activation of the comp...
Complement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effective, but...
Contains fulltext : 155109.pdf (publisher's version ) (Closed access
The complement system has obtained renewed clinical focus due to increasing number of patients treat...
Hemolytic uremic syndrome related to Shiga-toxin-secreting Escherichia coli infection (STEC-HUS) rem...
AbstractComplement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effect...
Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti-c...
Eculizumab is an anti-complement C5 monoclonal antibody which has greatly improved the prognosis and...
This manuscript presents quantitative findings on the actual effectiveness of terminal complement co...
Abstract Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of ...
the editor: Eculizumab fails to inhibit generation of C5a in vivo Eculizumab is a monoclonal antibod...
BACKGROUND: Hemolytic uremic syndrome related to Shiga-toxin-secreting Escherichia coli infection (S...
Abstract Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim progn...
The C5 targeting monoclonal antibody eculizumab has changed the natural history of paroxysmal noctur...
Background: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis ...
Eculizumab inhibits the terminal, lytic pathway of complement by blocking the activation of the comp...
Complement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effective, but...
Contains fulltext : 155109.pdf (publisher's version ) (Closed access
The complement system has obtained renewed clinical focus due to increasing number of patients treat...
Hemolytic uremic syndrome related to Shiga-toxin-secreting Escherichia coli infection (STEC-HUS) rem...
AbstractComplement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effect...
Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti-c...
Eculizumab is an anti-complement C5 monoclonal antibody which has greatly improved the prognosis and...
This manuscript presents quantitative findings on the actual effectiveness of terminal complement co...
Abstract Background C3 Glomerulopathy (C3G) is a rare glomerular disease caused by dysregulation of ...
the editor: Eculizumab fails to inhibit generation of C5a in vivo Eculizumab is a monoclonal antibod...
BACKGROUND: Hemolytic uremic syndrome related to Shiga-toxin-secreting Escherichia coli infection (S...
Abstract Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim progn...
The C5 targeting monoclonal antibody eculizumab has changed the natural history of paroxysmal noctur...
Background: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis ...